CircNOX4 promotes proliferation and resistance by regulating the hsa-miR-6884-5p/YWHAG Axis and ERK signaling pathway in cholangiocarcinoma
- PMID: 40736609
- DOI: 10.1007/s10142-025-01668-0
CircNOX4 promotes proliferation and resistance by regulating the hsa-miR-6884-5p/YWHAG Axis and ERK signaling pathway in cholangiocarcinoma
Abstract
The biological function of circular RNAs (circRNAs) has been increasingly implicated in tumor drug resistance. However, their role in intrahepatic cholangiocarcinoma (ICC) remains poorly understood, and the underlying mechanisms are largely unexplored. In this study, we identified a key circRNA, circNOX4, through data mining and experimental validation in ICC. We found that circNOX4 was significantly upregulated in ICC tissues and its expression correlated with advanced clinicopathological features. Functional assays demonstrated that circNOX4 promoted ICC cell proliferation and tumor growth both in vitro and in vivo. Mechanistically, circNOX4 acted as a molecular sponge for hsa-miR-6884-5p, thereby upregulating YWHAG expression. YWHAG, in turn, interacted with RAF1, enhancing its phosphorylation and activating the ERK signaling pathway. This led to the nuclear translocation of phosphorylated ERK and subsequent promotion of ICC progression. Furthermore, we found that circNOX4 attenuated the anti-tumor efficacy of Trametinib. In summary, circNOX4 contributes to ICC progression and drug resistance through the hsa-miR-6884-5p/YWHAG/ERK axis, and may serve as a potential diagnostic marker, prognostic indicator, and therapeutic target in ICC.
Keywords: Cholangiocarcinoma; CircNOX4; RAF/MEK/ERK signaling; Resistance; YWHAG.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Conflict of interest: The authors have declared no conflicts of interest. Informed consent: allowing the use of retrospective data at the time of admission was obtained from all patients included in the study, and specific consent was waived. Clinical trial number: Not applicable.
References
-
- Hammond SM (2015) An overview of MicroRNAs. Adv Drug Deliv Rev 87
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
